Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Schertz, TX
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Schertz, TX
Click here to add this to my saved trials
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Council Bluffs, IA
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Scottdale, PA
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scottdale, PA
Click here to add this to my saved trials
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Shavano Park, TX
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Shavano Park, TX
Click here to add this to my saved trials
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sugar Land, TX
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers
A Feasibility Study of Retinal Screening Using the RetinaVue 100 Hand- Held (Non-mydriatic) Camera in Outpatient Dialysis Centers
Status: Enrolling
Updated:  12/31/1969
UNC Ophthalmology
mi
from
Chapel Hill, NC
Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers
A Feasibility Study of Retinal Screening Using the RetinaVue 100 Hand- Held (Non-mydriatic) Camera in Outpatient Dialysis Centers
Status: Enrolling
Updated: 12/31/1969
UNC Ophthalmology
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Insulin Balanced Infusion System
Insulin Balanced Infusion System Control of Glucose
Status: Enrolling
Updated:  12/31/1969
3113 Lawton Road
mi
from
Orlando, FL
Insulin Balanced Infusion System
Insulin Balanced Infusion System Control of Glucose
Status: Enrolling
Updated: 12/31/1969
3113 Lawton Road
mi
from
Orlando, FL
Click here to add this to my saved trials
Canagliflozin-Mealtime Insulin Rescue
Canagliflozin-Mealtime Insulin Rescue
Status: Enrolling
Updated:  12/31/1969
Atlanta VA Medical Center
mi
from
Decatur, GA
Canagliflozin-Mealtime Insulin Rescue
Canagliflozin-Mealtime Insulin Rescue
Status: Enrolling
Updated: 12/31/1969
Atlanta VA Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials
Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus
Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus
Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Dapagliflozin Patient Satisfaction Survey
Direct to Patient Survey to Examine Treatment Satisfaction and Experience With Dapagliflozin Compared to Sulfonylureas
Status: Enrolling
Updated:  12/31/1969
Reasearch Site
mi
from
Eden Prairie, MN
Dapagliflozin Patient Satisfaction Survey
Direct to Patient Survey to Examine Treatment Satisfaction and Experience With Dapagliflozin Compared to Sulfonylureas
Status: Enrolling
Updated: 12/31/1969
Reasearch Site
mi
from
Eden Prairie, MN
Click here to add this to my saved trials
Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices
Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices
Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
T1DM Immunotherapy Using Polyclonal Tregs + IL-2
A Phase 1 Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy With Interleukin-2 for the Treatment of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
T1DM Immunotherapy Using Polyclonal Tregs + IL-2
A Phase 1 Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy With Interleukin-2 for the Treatment of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
T1DM Immunotherapy Using Polyclonal Tregs + IL-2
A Phase 1 Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy With Interleukin-2 for the Treatment of Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Yale University
mi
from
New Haven, CT
T1DM Immunotherapy Using Polyclonal Tregs + IL-2
A Phase 1 Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy With Interleukin-2 for the Treatment of Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston/The Medical Center
mi
from
Houston, TX
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston/The Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston/Katy office
mi
from
Katy, TX
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston/Katy office
mi
from
Katy, TX
Click here to add this to my saved trials
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
Kingwood, TX
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
Kingwood, TX
Click here to add this to my saved trials
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
The Woodlands, TX
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Newport Beach, CA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Walnut Creek, CA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Haven, CT
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Doral, FL
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Doral, FL
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Gainesville, FL
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, GA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boise, ID
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baton Rouge, LA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Worcester, MA
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Morristown, NJ
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mentor, OH
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mentor, OH
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sioux Falls, SD
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Schertz, TX
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Schertz, TX
Click here to add this to my saved trials
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Webster, TX
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials